Of the 15 patients who were prematurely discontinued from the study, six discontinued as permitted by the protocol due to uncontrolled acromegaly (GH > 2·5 μg/l and/or IGF-1 above the upper limit of normal (ULN) for age), one withdrew consent and eight patients withdrew because of adverse events (AEs). This evidence concerns the gene IGF1 and acromegaly.